POWERFUL LESION REDUCTION
FOR EVEN MORE PATIENTS

Early results as soon as 2 weeks with consistent beneficial
results after 7 weeks1

Mean lesion reduction from two vehicle-controlled 12 week trials with acne
subjects using RETIN-A MICRO 0.1% once daily1

Non-inflammatory

Study 1

49%*

vs 22%* for vehicle

Study 2

32%†

vs 3%‡ for vehicle

Inflammatory

Study 1

37%*

vs 18%* for vehicle

Study 2

29%†

vs 24%‡ for vehicle

*n=72; †n=71; ‡n=67

RETIN-A MICRO 0.1% was significantly superior to the vehicle

Mean lesion reduction from two vehicle-controlled 12 week trials with acne
subjects using RETIN-A MICRO 0.04% once daily1

Non-inflammatory

Study 3

37%*

vs -2%† for vehicle

Study 4

29%‡

vs 14% for vehicle

Inflammatory

Study 3

44%*

vs 13%† for vehicle

Study 4

41%‡

vs 30% for vehicle

*n=108; †n=110; ‡n=111; n=103

p<0.05

FOR MORE PATIENTS THAN EVER

tolerability THEY SHOULD EXPECT

98.7% (222/225) and 94% (210/224) of patients foundRETIN-A MICRO to be tolerable in clinical studies1

In the 0.04% study no severe irritation was reported at week 2, the typical peakof irritation, and only 1.3% (3/225) of subjects discontinued due to irritation

In the 0.1% study no more than 3% of subjects reported severe irritationand only 6% (14/224) discontinued as a result

RETIN-A MICRO should not be used on eczematous or sunburned skindue to potential for severe irritation.

Avoid use of RETIN-A MICRO with weather extremes, such as wind or colddue to potential for increased irritation.

FOR MORE PATIENTS THAN EVER

tolerability THEY SHOULD EXPECT

98.7% (222/225) and 94% (210/224) of patients found RETIN-A MICRO to be tolerable in clinical studies1

In the 0.04% study no severe irritation was reported at week 2, the typical peak of irritation, and only 1.3% (3/225) of subjects discontinued due to irritation

In the 0.1% study no more than 3% of subjects reported severe irritation and only 6% (14/224) discontinued as a result

RETIN-A MICRO should not be used on eczematous or sunburned skin due to potential for severe irritation.

Avoid use of RETIN-A MICRO with weather extremes, such as wind or cold due to potential for increased irritation.

MORE PATIENTS,
SAME DELIVERY SYSTEM

MORE PATIENTS, SAME DELIVERY SYSTEM

Retin-A Micro with Microsponge delivery system technology

• Helps control the release of tretinoin2

• Improves photostability, even in the presence
of benzoyl peroxide3

• Found to significantly reduce appearance of facial shine4*

Pump-controlled dispensing

• Allows for consistent dosing at either strength1,4

• Designed with patients in mind

*Results from a single-center, double-blind, half-face study comparing RETIN-A MICRO 0.1% vs. tretinoin cream 0.025%. At baseline, 77.2% of faces had moderate to severe oiliness. With RETIN-A MICRO 0.1%, only 45.7% of faces had moderate to severe oiliness after 3 hours [P = 0.008] and only 34.3% of faces had moderate to severe oiliness after 6 hours [P<0.001].

Coordinator and subjects used a 4-point scale [0=none, 1=mild (very little), 2=moderate, 3=severe (very oily)] to assess facial oiliness.

Indication

RETIN-A MICRO (tretinoin gel) microsphere is indicated for topical application in the treatment of acne vulgaris.

Important Safety Information

The skin of certain individuals may become excessively dry, red, swollen or blistered during the use of RETIN-A MICRO.

Tretinoin has been reported to cause severe irritation on eczematous skin and should be used with utmost caution in patients with this condition.

If warranted, patients should temporarily reduce the amount or frequency of application, or discontinue use temporarily or altogether. If a reaction suggesting sensitivity occurs, use should be discontinued.

Unprotected exposure to sunlight, including sunlamps, should be minimized during the use of RETIN-A MICRO, and patients with sunburn should be advised not to use the product until fully recovered because of heightened susceptibility to sunlight with the use of tretinoin.

Patients should be encouraged to use a sunscreen with a SPF of 15 or higher and protective clothing over treated areas when exposure cannot be avoided.

Weather extremes, such as wind or cold, also may be irritating to patients under treatment with tretinoin.

The most common adverse events are mild to moderate irritation (erythema, peeling, dryness, burning/stinging, or itching of the skin).

RETIN-A MICRO should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, and caution should be exercised in prescribing for nursing mothers. Safety and efficacy in patients under 12 have not been established.

To report SUSPECTED ADVERSE REACTIONS, contact Ortho Dermatologics at 1-800-321-4576 or FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.

Please click here for full Prescribing Information.

This offer is only valid for patients with commercial insurance. Eligible uninsured patients will pay more. This offer is not valid for any person eligible for reimbursement of prescriptions, in whole or in part, by any federal, state, or other governmental programs, including, but not limited to, Medicare (including Medicare Advantage and Part A, B, and D plans), Medicaid, TRICARE, Veterans Administration or Department of Defense health coverage, CHAMPUS, the Puerto Rico Government Health Insurance Plan, or any other federal or state health care programs. This offer is good only in the U.S. at retail pharmacies owned and operated by Walgreen Co. (or its affiliates) or other participating independent retail pharmacies. This offer is not valid in Massachusetts or Minnesota or where otherwise prohibited, taxed or otherwise restricted. Click here for other terms and conditions that apply.

References: 1. Retin-A Micro Gel Package Insert. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC. 2. Thielitz A, Gollnick H. Topical retinoids in acne vulgaris: update on efficacy and safety. Am J Clin Dermatol. 2008;9(6):369-381. 3. Nighland M, Yusuf M, Wisniewski S, Huddleston K, Nyirady J. The effect of simulated solar UV irradiation on tretinoin in tretinoin gel microsphere 0.1% and tretinoin gel 0.025%. Cutis. 2006;77(5):313-316. 4. Eichenfield LF, Nighland M, Rossi AB, et al; PUMP Study Group. Phase 4 study to assess tretinoin pump for the treatment of facial acne. J Drugs Dermatol. 2008;71(12):1129-1136.

Microsponge is a registered trademark of AMCOL International Corporation.© All Rights Reserved. RAM.0041.USA.18

CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION

Indication

RETIN-A MICRO (tretinoin gel) microsphere is indicated for topical application in the treatment of acne vulgaris.

Important Safety Information

The skin of certain individuals may become excessively dry, red, swollen or blistered during the use of RETIN-A MICRO.

Tretinoin has been reported to cause severe irritation on eczematous skin and should be used with utmost caution in patients with this condition.

If warranted, patients should temporarily reduce the amount or frequency of application, or discontinue use temporarily or altogether. If a reaction suggesting sensitivity occurs, use should be discontinued.

Unprotected exposure to sunlight, including sunlamps, should be minimized during the use of RETIN-A MICRO, and patients with sunburn should be advised not to use the product until fully recovered because of heightened susceptibility to sunlight with the use of tretinoin.

Patients should be encouraged to use a sunscreen with a SPF of 15 or higher and protective clothing over treated areas when exposure cannot be avoided.

Weather extremes, such as wind or cold, also may be irritating to patients under treatment with tretinoin.

The most common adverse events are mild to moderate irritation (erythema, peeling, dryness, burning/stinging, or itching of the skin).

RETIN-A MICRO should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, and caution should be exercised in prescribing for nursing mothers. Safety and efficacy in patients under 12 have not been established.

To report SUSPECTED ADVERSE REACTIONS, contact Ortho Dermatologics at 1-800-321-4576 or FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.

Please click here for full Prescribing Information.